Wenyong Wu
Impact in
- Immunology top 5%
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- Oncology top 5%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Papers in
-
- MicroRNA in disease regulation 8
-
- Circular RNAs in diseases 3
- RNA modifications and cancer 3
- Ubiquitin and proteasome pathways 2
- Co-authors
- Haiming Wei (1 shared paper)Jiacheng Bi (1 shared paper)Hua Wang (1 shared paper)Xiaodong Zheng (1 shared paper)Zhigang Tian (1 shared paper)Qing Zhang (1 shared paper)Rui Sun (1 shared paper)Yongyan Chen (1 shared paper)
- Journals
- PLoS ONE (3 papers)BMC Cancer (3 papers)Oncotarget (3 papers)The FASEB Journal (1 paper)International Immunopharmacology (1 paper)
- Partner nations
- ChinaSingaporeSouth Korea
In The Last Decade
Wenyong Wu
27 papers receiving 1.5k citations
Wenyong Wu's Hit Papers
Peers
Comparison fields: 5 of 85
- Immunology 688
- Oncology 632
- Cancer Research 288
- Molecular Biology 460
- Immunology and Allergy 21
Countries citing papers authored by Wenyong Wu
This map shows the geographic impact of Wenyong Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenyong Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenyong Wu more than expected).
Fields of papers citing papers by Wenyong Wu
This network shows the impact of papers produced by Wenyong Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenyong Wu. The network helps show where Wenyong Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Wenyong Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 30 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity Hit paper breakdown → | 2018 | 835 |
| 2 | 2012 | 159 | |
| 3 | 2011 | 66 | |
| 4 | 2020 | 41 | |
| 5 | 2018 | 39 | |
| 6 | 2016 | 38 | |
| 7 | 2013 | 36 | |
| 8 | 2015 | 29 | |
| 9 | 2014 | 25 | |
| 10 | 2014 | 19 | |
| 11 | 2017 | 19 | |
| 12 | 2011 | 18 | |
| 13 | 2017 | 18 | |
| 14 | 2022 | 17 | |
| 15 | 2021 | 15 | |
| 16 | 2014 | 15 | |
| 17 | 2023 | 15 | |
| 18 | 2021 | 15 | |
| 19 | 2016 | 15 | |
| 20 | 2013 | 13 |
About Wenyong Wu
Wenyong Wu is a scholar working on Cancer Research, Molecular Biology, Epidemiology, Oncology and Pulmonary and Respiratory Medicine, having authored 30 papers that have together received 1.5k indexed citations. Recurring topics across this work include MicroRNA in disease regulation (8 papers), Autophagy in Disease and Therapy (4 papers), Circular RNAs in diseases (3 papers), Cytokine Signaling Pathways and Interactions (3 papers), RNA modifications and cancer (3 papers), Ubiquitin and proteasome pathways (2 papers), Ferroptosis and cancer prognosis (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). The work is most often cited by research in Immunology (688 citations), Oncology (632 citations), Cancer Research (288 citations), Molecular Biology (460 citations) and Immunology and Allergy (21 citations). Wenyong Wu has collaborated with scholars based in China, Singapore and South Korea. Frequent co-authors include Haiming Wei, Jiacheng Bi, Hua Wang, Xiaodong Zheng, Zhigang Tian, Qing Zhang, Rui Sun, Yongyan Chen, Zhengguang Wang and Hui Peng. Their work appears in journals such as PLoS ONE, BMC Cancer, Oncotarget, The FASEB Journal and International Immunopharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.